sur VALBIOTIS (EPA:ALVAL)
Valbiotis SA: 2025 Review and 2026 Objectives
Valbiotis SA unveiled its 2025 annual results, highlighting a solid strategic presence in the French and international markets. Revenue increased significantly, reaching €905,000 compared to €175,000 in 2024, thanks to an expanding product portfolio. In France, the company doubled its pharmacy listings, fueling significant sales growth in the fourth quarter, with €400,000 in revenue.
Internationally, Valbiotis signed key partnerships, particularly in Asia and the Middle East, strengthening its global presence. Despite a 30% decrease in operating expenses, the company reinforced its development strategy with an intensified sales focus. Net income for 2025 was -€9.417 million, an improvement compared to the previous year.
In 2026, commercial deployment will continue with the activation of strategic agreements in Asia and the Middle East, supporting the ambitious growth prospects set until 2030.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS